Bioverge

Bringing A Hub-and-Spoke Business Model to Regenerative Medicine

Nov 1, 2023
Guest
Faizzan Ahmad
Faizzan Ahmad, Co-Founder and CEO of Cure8bio, discusses their hub-and-spoke model in regenerative medicine, the benefits of a diverse portfolio, Schwann cell transplantation, de-differentiation therapy for fibrosis, A VAIL for drug discovery, making go-no-go decisions, and the role of a strong central hub in regenerative medicine.
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 2min
2
Building a Diverse Portfolio in Regenerative Medicine
01:49 • 22min
3
Creating Schwann Cells for Nerve Regeneration and Transplantation
24:19 • 3min
4
Developing a Peptide-Induced De-Differentiation Therapy for Fibrosis
26:56 • 2min
5
A VAIL: De-risking Drug Discovery
29:11 • 4min
6
Building a Broad Portfolio and Making Go-No-Go Decisions
33:28 • 9min
7
The Role of a Strong Central Hub in Regenerative Medicine
42:28 • 2min